{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:45:43Z","timestamp":1782287143704,"version":"3.54.5"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background. Personalized therapy is becoming increasingly popular in oncological scenarios, not only based on molecular pharmacological targets, but also preventing any drug\u2013drug\u2013gene interaction (DDGI), which could lead to severe toxicities. Single nucleotide polymorphisms (SNPs), the individual germline sequence variations in genes involved in drug metabolism, are correlated to interindividual response to drugs and explain both efficacy and toxicity profiles reported by patients. Case presentation. We present the case of a woman suffering from triple-positive breast cancer; she had early-stage disease at the onset and after four years developed metastatic disease. During her history, she presented different toxicities due to antineoplastic treatments. Particularly, hypertransaminasemia was found during every line of treatment. Nevertheless, we were able to guarantee the patient an excellent therapeutic adhesion thanks to the supportive treatments and the reduction of drug dosage. Moreover, we conducted a simultaneous analysis of the patient\u2019s biochemical and genomic data thanks to Drug-PIN software, and we found several significant SNPs of the main enzymes and transporters involved in drug metabolism. Conclusion. Our case report demonstrated the relevance of DDGI in clinical practice management of a patient treated for advanced breast cancer, suggesting the role of Drug-PIN software as an easy-to-use tool to prevent adverse events during cancer treatment and to help physicians in therapeutic algorithms. However, further studies are needed to confirm these results.<\/jats:p>","DOI":"10.3390\/curroncol28030184","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:14:21Z","timestamp":1621948461000},"page":"1980-1987","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)"],"prefix":"10.3390","volume":"28","author":[{"given":"Martina","family":"Panebianco","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Oncology Unit, Sant\u2019 Andrea Hospital, University \u201cLa Sapienza\u201d, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Taurelli Salimbeni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Oncology Unit, Sant\u2019 Andrea Hospital, University \u201cLa Sapienza\u201d, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-8348","authenticated-orcid":false,"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Oncology Unit, Sant\u2019 Andrea Hospital, University \u201cLa Sapienza\u201d, 00167 Rome, Italy"},{"name":"Department of Medical-Surgical Sciences and Translation Medicine, Sant\u2019 Andrea Hospital, University \u201cLa Sapienza\u201d, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9064-8761","authenticated-orcid":false,"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Oncology Unit, Sant\u2019 Andrea Hospital, University \u201cLa Sapienza\u201d, 00167 Rome, Italy"},{"name":"Oncology Unit, Istituto Dermopatico Dell\u2019Immacolata\u2014Istituti di Ricovero e Cura a Carattere Scientifico of Rome, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Roberto, M., Rossi, A., Panebianco, M., Pomes, L., Arrivi, G., Ierin\u00f2, D., Simmaco, M., Marchetti, P., and Mazzuca, F. (2021). Drug\u2013Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN\u00ae System Comprehensive Approach. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010067"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/17512433.2014.910111","article-title":"Understanding and preventing drug\u2013drug and drug\u2013gene interactions","volume":"7","author":"Tannenbaum","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/FPC.0000000000000346","article-title":"Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing","volume":"29","author":"Lee","year":"2019","journal-title":"Pharm. Genom."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/pgs.14.6","article-title":"How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping","volume":"15","author":"Verbeurgt","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics\u2014Drug Disposition, Drug Targets, and Side Effects","volume":"348","author":"Evans","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bjc.6601574","article-title":"SNPs in cancer research and treatment","volume":"90","author":"Erichsen","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25355","DOI":"10.18632\/oncotarget.25256","article-title":"SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand","volume":"9","author":"Palmirotta","year":"2018","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.21873\/anticanres.11610","article-title":"Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes","volume":"37","author":"Angelini","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.canep.2013.04.012","article-title":"Influence of ABCB1 genetic variants in breast cancer treatment outcomes","volume":"37","author":"Chaturvedi","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4143\/crt.2015.360","article-title":"Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy","volume":"48","author":"Abba","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Etienne-Grimaldi, M.-C., Boyer, J.-C., Beroud, C., Mbatchi, L., Van Kuilenburg, A., Bobin-Dubigeon, C., Thomas, F., Chatelut, E., Merlin, J.-L., and Pinguet, F. (2017). New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175998"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pascual, T., Apell\u00e1niz-Ruiz, M., Pernaut, C., Cueto-Felgueroso, C., Villalba, P., \u00c1lvarez, C., Manso, L., Inglada-P\u00e9rez, L., Robledo, M., and Rodriguez-Antona, C. (2017). Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180192"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2217\/pgs.14.127","article-title":"SNPs and taxane toxicity in breast cancer patients","volume":"15","author":"Boso","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/pgs-2017-0006","article-title":"Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients","volume":"18","author":"Sini","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10549-020-05603-8","article-title":"Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015","volume":"181","author":"Trubetskoy","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2217\/pgs.12.165","article-title":"Pharmacogenetics of taxanes: Impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity","volume":"13","author":"Jabir","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/jcpt.12797","article-title":"Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India","volume":"44","author":"Priyadarshini","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1111\/1759-7714.13184","article-title":"ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy","volume":"10","author":"Zhong","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/annonc\/mdn698","article-title":"Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: Clinical evidence of a role of oxidative stress in taxane toxicity","volume":"20","author":"Mir","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","article-title":"Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms","volume":"79","author":"Tran","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12282-014-0547-x","article-title":"Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer","volume":"23","author":"Sugishita","year":"2014","journal-title":"Breast Cancer"},{"key":"ref_22","first-page":"199","article-title":"Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer","volume":"124","author":"Zhang","year":"2011","journal-title":"Chin. Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29789","DOI":"10.18632\/oncotarget.25712","article-title":"GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: A comprehensive analysis using targeted resequencing of 100 pharmacogenes","volume":"9","author":"Yoshihama","year":"2018","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","article-title":"Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone*","volume":"64","author":"Heiskanen","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.pnpbp.2006.03.018","article-title":"Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer","volume":"30","author":"Susce","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1533-2500.2007.00153.x","article-title":"Complicated Pain Management in a CYP450 2D6 Poor Metabolizer","volume":"7","author":"Foster","year":"2007","journal-title":"Pain Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid Metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1200\/JCO.2005.02.1295","article-title":"Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer","volume":"24","author":"Wong","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-018-3751-0","article-title":"Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: Correlations with pharmacokinetics and MDR1 polymorphisms","volume":"83","author":"Gusella","year":"2019","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/3\/184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:30Z","timestamp":1760162850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/3\/184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["curroncol28030184"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28030184","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}